Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Epanova vs Lovaza in Patients with Hypertriglyceridemia and History of Pancreatitis
NCT02189252Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve 0-24h for Plasma Total EPA + Total DHA and Maximum Plasma Concentration for Plasma Total EPA + Total DHA. Started Oct 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02189252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189252.